Suchergebnisse - "Smith, Terry J"

PubPharm (18)

1

Teprotumumab Divergently Alters Fibrocyte Gene Expression : Implications for Thyroid-associated Ophthalmopathy

enthalten in: The Journal of clinical endocrinology and metabolism | 2022

von Fernando, R. | Smith, T.

2

Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease

enthalten in: The Journal of clinical endocrinology and metabolism | 2022

von Smith, T.

ErratumIn: J Clin Endocrinol Metab. 2023 Feb 15;108(3):e46. - PMID 36513816

3

Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2021

von Fernando, R. | Caldera, O. | Smith, T.

CommentIn: Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):. - PMID 35086933

4

Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy

enthalten in: Cells | 2021

von Janssen, J. | Smith, T.

5

Insulin-Like Growth Factor Pathway and the Thyroid

enthalten in: Frontiers in endocrinology | 2021

von Smith, T.

6

Teprotumumab : a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy

enthalten in: Expert opinion on investigational drugs | 2020

von Slentz, D. | Nelson, C. | Smith, T.

7

Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy

enthalten in: Frontiers in endocrinology | 2020

von Smith, T.

8

Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy

enthalten in: Expert opinion on investigational drugs | 2020

von Slentz, D. | Nelson, C. | Smith, T.

9

Challenges in Orphan Drug Development : Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy

enthalten in: Annual review of pharmacology and toxicology | 2019

von Smith, T.

10

Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?

enthalten in: Expert opinion on orphan drugs | 2018

von Smith, T.